At 9.8% CAGR, the Europe Antimicrobial Surgical Suture Market is Projected to be Worth US$ 252.11 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Europe antimicrobial surgical suture market was valued at US$ 119.72 in 2023 and is expected to reach US$ 252.11 million by 2031, registering a CAGR of 9.8% from 2024 to 2031. Increasing cases of chronic wounds and surging prevalence of surgical site infections are among the critical factors attributed to the Europe antimicrobial surgical suture market expansion.

Sutures are frequently used to close post-operative wounds and to treat deep wounds caused during road and occupational accidents, orthopedic injuries, and sports injuries, owing to their ability to stimulate natural healing. Suturing has significantly transformed the wound closure process by accelerating it. However, wound care management is a complex process and surgical site infections are the most common medical infections observed among the large population. As per the European Centre for Disease Prevention and Control, between 2018 and 2020, 12 EU Member States and one EEA country reported 19,680 surgical site infections (SSIs) from 1,255,958 surgical procedures across nine types of surgeries. The percentage of SSIs varied significantly based on the type of procedure, ranging from 0.6% for knee prosthesis surgery to 9.5% for open colon surgery. According to WHO, in low- and middle-income countries, 11% of patients who undergo surgery develop an infection during the process. To fight against surgical site infections, scientists have developed nanosilver-impregnated silk sutures. Nanosilver possesses antimicrobial properties, and its optical and structural characteristics make it an appealing candidate for biomedical applications. The increasing number of cases of surgical site infections is driving the need for sutures that have antimicrobial properties. In July 2022, Dolphin Sutures launched its antibacterial range of antibacterial sutures containing Triclosan coating, which is a known broad-spectrum antibacterial and antifungal agent. Therefore, increasing prevalence of surgical site infections are expected to create demand for antimicrobial surgical sutures and drive the growth of antimicrobial surgical sutures market.

On the contrary, non-invasive alternatives to stitches hampers the growth of Europe antimicrobial surgical suture market.

Based on type, the Europe antimicrobial surgical suture market is bifurcated into triclosan antimicrobial suture and chlorhexidine antimicrobial suture. The triclosan antimicrobial suture segment held 69.4% share of the Europe antimicrobial surgical suture market in 2023, amassing US$ 83.13 million. It is projected to garner US$ 177.25 million by 2031 to expand at 10.0% CAGR during 2024–2031.

By raw materials, the Europe antimicrobial surgical suture market is segmented into polyglactin 910 antimicrobial suture, poliglecaprone 25, and polyglycolic acid. The polyglactin 910 antimicrobial suture segment held 59.0% share of the Europe antimicrobial surgical suture market in 2023, amassing US$ 70.64 million. It is projected to garner US$ 149.27 million by 2031 to expand at 9.9% CAGR during 2024–2031.

By application, the Europe antimicrobial surgical suture market is segmented into cardiovascular surgery, general surgery, ophthalmic surgery, gynecological surgery, orthopedic surgery, plastic surgery, veterinary surgery, dental surgery, and others. The cardiovascular surgery segment held 34.2% share of the Europe antimicrobial surgical suture market in 2023, amassing US$ 40.89 million. It is projected to garner US$ 84.11 million by 2031 to expand at 9.5% CAGR during 2024–2031.

By end user, the Europe antimicrobial surgical suture market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals surgery segment held 46.9% share of the Europe antimicrobial surgical suture market in 2023, amassing US$ 56.14 million. It is projected to garner US$ 116.10 million by 2031 to expand at 9.6% CAGR during 2024–2031.

Based on country, the Europe antimicrobial surgical suture market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany held 29.2% share of Europe antimicrobial surgical suture market in 2023, amassing US$ 34.93 million. It is projected to garner US$ 72.76 million by 2031 to expand at 9.7% CAGR during 2024–2031.

Key players operating in the Europe antimicrobial surgical suture market are TI Medical; Healthium Medtech Limited; Meril Life Sciences Pvt Ltd; Unilene; Johnson & Johnson; Futura Surgicare Pvt Ltd (Dolphin Sutures); Cencora, Inc. (AmerisourceBergen Corporation); Advanced MedTech Solutions Pvt. Ltd.; and Internacional Farmacéutica SA, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com